Literature DB >> 9021211

Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.

X S Pan1, L M Fisher.   

Abstract

gyrA and parC mutations have been identified inn Streptococcus pneumoniae mutants stepwise selected for resistance to sparfloxacin, an antipneumococcal fluoroquinolone. GyrA mutations (at the position equivalent to resistance hot spot Ser-83 in Escherichia coli GyrA) were found in all 17 first-step mutants examined and preceded DNA topoisomerase IV parC mutations (at Ser-79 or Glu-83), which appeared only in second-step mutants. The targeting of gyrase by sparfloxacin in S. pneumoniae but of topoisomerase IV by ciprofloxacin indicates that target preference can be altered by changes in quinolone structure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021211      PMCID: PMC163733     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication.

Authors:  D E Adams; E M Shekhtman; E L Zechiedrich; M B Schmid; N R Cozzarelli
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

2.  4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction.

Authors:  M Oram; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

3.  Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  S Sreedharan; L R Peterson; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

4.  Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

Authors:  X S Pan; J Ambler; S Mehtar; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 5.  New quinolones and gram-positive bacteria.

Authors:  L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

6.  DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli.

Authors:  S Sreedharan; M Oram; B Jensen; L R Peterson; L M Fisher
Journal:  J Bacteriol       Date:  1990-12       Impact factor: 3.490

7.  Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.

Authors:  H Yoshida; M Bogaki; M Nakamura; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

8.  Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.

Authors:  L Ferrero; B Cameron; B Manse; D Lagneaux; J Crouzet; A Famechon; F Blanche
Journal:  Mol Microbiol       Date:  1994-08       Impact factor: 3.501

9.  Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.

Authors:  H Ito; H Yoshida; M Bogaki-Shonai; T Niga; H Hattori; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

10.  Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis.

Authors:  V Korten; W M Huang; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

View more
  102 in total

1.  Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.

Authors:  V J Heaton; C E Goldsmith; J E Ambler; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 2.  The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults.

Authors:  P J Moss; R G Finch
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

3.  New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.

Authors:  C Janoir; E Varon; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

4.  In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Authors:  M Boos; S Mayer; A Fischer; K Köhrer; S Scheuring; P Heisig; J Verhoef; A C Fluit; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.

Authors:  M Takei; H Fukuda; R Kishii; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

6.  Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  D J Bast; J C de Azavedo; T Y Tam; L Kilburn; C Duncan; L A Mandell; R J Davidson; D E Low
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

Review 7.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

8.  Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium.

Authors:  N A el Amin; S Jalal; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

9.  Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

10.  In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.

Authors:  T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.